These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8668609)

  • 1. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia?
    Young JB
    Pharmacotherapy; 1996; 16(2 Pt 2):78S-84S. PubMed ID: 8668609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inodilator therapy for heart failure. Early, late, or not at all?
    Remme WJ
    Circulation; 1993 May; 87(5 Suppl):IV97-107. PubMed ID: 8097971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of current and investigational pharmacologic agents for acute heart failure syndromes.
    Shin DD; Brandimarte F; De Luca L; Sabbah HN; Fonarow GC; Filippatos G; Komajda M; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):4A-23A. PubMed ID: 17239703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotropes in the management of acute heart failure.
    Petersen JW; Felker GM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of congestive heart failure: is the role of positive inotropic therapy fading?
    Futterman LG; Lemberg L
    Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rational use of catecholamines and inotropes].
    Hewing B; Stangl K
    Pneumologie; 2007 Nov; 61(11):700-8. PubMed ID: 17929214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotropic therapy is unsuccessful: wrong conceptual target or wrong therapeutic tools?
    Rapezzi C; Perugini E; Santi M; Bracchetti G; Branzi A
    Ital Heart J; 2003 May; 4 Suppl 2():22S-26S. PubMed ID: 14635366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure].
    Tamargo J; López-Sendón J
    Rev Esp Cardiol; 2004 May; 57(5):447-64. PubMed ID: 15151778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasodilators and inotropic agents in the treatment of congestive heart failure.
    Francis GS
    Semin Nephrol; 1994 Sep; 14(5):464-78. PubMed ID: 7997651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of inotropic agents.
    Vroom MB
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blocking agents and positive inotropic agents in the therapy of chronic heart failure.
    Erdmann E; Schwinger R; Böhm M
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S138-44. PubMed ID: 11527118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic determinants of survival in congestive heart failure. The survival hypothesis: how small uncontrolled studies should influence the design of large-scale clinical trials.
    Francis GS
    Circulation; 1987 May; 75(5 Pt 2):IV74-9. PubMed ID: 3568319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion therapy in severe heart failure. A reappraisal.
    Campana C; Scelsi L; Serio A
    Ital Heart J; 2003 May; 4 Suppl 2():15S-21S. PubMed ID: 14635365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropic therapy: an important role in the treatment of advanced symptomatic heart failure.
    McCann P; Hauptman PJ
    Med Clin North Am; 2012 Sep; 96(5):943-54. PubMed ID: 22980057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.